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Abstract 
Purpose: To characterize diclofenac sodium (DS) liposomes prepared using palm oil fractions. 
Methods: Reverse-phase evaporation method was used to prepare liposomes containing 10, 20, 30 , 
40  or 50% palm oil fractions. The effect of palm oil content on liposome formation, surface morphology, 
shape, size and zeta potential of the liposomes were studied using scanning electron microscopy (SEM) 
transmission electron microscopy (TEM) and particle analyzer. Drug loading, entrapment efficiency and 
in vitro drug release were measured in phosphate-buffered saline (PBS, pH 7.4) by UV 
spectrophotometry. 
Results TEM and SEM images showed formation of liposomes for all formulations, However, increase 
in the proportion of palm oil in the formulations significantly reduced particle size and increased zeta 
potential. The effect on drug loading and drug release varied with palm oil fraction. The best release 
pattern with appropriate entrapment efficiency and stability was obtained with liposomes containing 33 
% palm oil fraction. Introduction of 46 and 56 % of palm oil fractions yielded zeta potential of -42.8 and -
50.7 mV, respectively, compared with -31.2 mV for the formulation without palm oil.  
Conclusion: The results demonstrate the potentials of palm oil fractions in the preparation of suitable 
DS liposomes with good bioavailability.  
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Liposome is uni- or multi-layered spherical 
vesicles mainly composed of phospholipids [1]. 
They are used to deliver both hydrophilic and 
hydrophobic drugs by various routes of 
administration such as oral, intramuscular, 
intraperitoneal, subcutaneous, inhalation and 
ocular routes [2]. Furthermore, liposomal 
encapsulation of drugs can provide targeted drug 
delivery and sustained release effect besides 
reduction of toxicity and adverse effects [3].  
 
Diclofenac sodium (DS) is widely used to treat 
mild to moderate pain and inflammations 
including those associated with osteo- and 
rheumatoid arthritis by inhibiting cyclooxygenase 
enzyme. Currently available DS dosage forms 
include gel, ophthalmic solution, immediate and 
controlled release tablets, suppositories and 
intramuscular injection [4]. Oral forms of DS are 
the most common in the market though they 
usually cause gastrointestinal problems such as 
abdominal cramps, nausea, constipation, 
diarrhea and peptic ulceration. Furthermore, 40 
% of the DS administered orally undergoes first-
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pass metabolism and does not reach systemic 
circulation [5]. Due to its poor solubility in water 
and acidic medium in the stomach, it has a poor 
oral bioavailability and a short half-life of about 
two hours [5]. 
 
Intramuscular injection of DS avoids first pass 
metabolism and achieves a faster therapeutic 
effect [6]. However, the intramuscular injection 
can cause cutaneous lesions at injection site. 
This problem can be solved by encapsulation of 
DS in liposomes where local tissue damage can 
be reduced and the DS release rate can be 
controlled [7].  
 
Palm oil mainly consists of fatty acids like 
palmitic, stearic, linoleic, oleic and myristic acids 
[8]. It has been widely researched for its 
nutritional and pharmaceutical properties, 
including antioxidant activities, cholesterol 
lowering, anti-cancer effects and protection 
against atherosclerosis owing to the presence of 
chemicals such as carotenes, tocopherols, 
tocotrienols, terpenoids, tannins, flavonoids, 
hydrocarbons and ketones [9].  
 
The main objectives of this study was to 
investigate the effect of palm oil fraction on 
formation of liposomes, to assess the stability of 
liposomal DS prepared by palm oil fraction, to 
investigate the in vitro drug release rate from 
new formulation of liposomal DS and to make 
recommendation based on the best formulation 
of liposomal DS prepared by palm oil fraction as 






L-alpha-phosphatidylcholine (PC), cholesterol 
(CH), linoleic acid, methanol and chloroform 
were purchased from Sigma-Aldrich, Germany. 
Diclofenac sodium (DS) was provided by Epic 
Ingredients Sdn. Bhd (Malaysia).. Palmetic acid, 
Oleic acid, Stearic acid and linoleic acid which 
are indicated as palm oil lipid portions were 
purchased from Acidchem International Sdn. Bhd 
(Malaysia). Sodium hydroxide and potassium 
dihydrogen phosphate were purchased from 
Merck, Germany. 
 
Preparation of liposomes 
 
Liposomes were prepared using conventional 
method [10] as per the composition in Table 1. 
Each formulation consisted of CH with varying 
levels of PC and fatty acids. The lipid 
components were dissolved in 
chloroform:methanol mixture (2:1, v/v) in a 
round-bottom flask. The solvent was removed 
under vacuum using a rotary evaporator 
(Rotavapour R-124, BÜCHI) at 50°C, 50 rpm. 
After a thin lipid film was formed in the interior of 
the flask, the system was purged with nitrogen to 
remove organic solvent completely. The lipid film 
was hydrated with 10 ml solution containing DS 
(20 µg/L) in phosphate-buffered saline (PBS, pH 
7.4). Finally, the mixture was sonicated for 15 
min in a bath-type sonicator (Sonicor). The 
liposomes were allowed to form at room 
temperature and kept in the refrigerator overnight 
[9]. The mixture was filtered through a syringe 




Transmission electron microscopy (TEM) and 
scanning electron microscopy (SEM) were used 
to characterize the surface and structure of the 
liposome, respectively. The samples were 
prepared for TEM, by applying a drop of the 
mixture to a carbon-coated copper grid, and left 
for one minute to allow some of the particles stick 
to on the carbon substrate. After removing the 
excess of dispersion with a piece of filter paper a 
drop of 1 % phosphotungstic acid solution was 
applied for one minute, and left to air-dry. The 
samples were then viewed under TEM 
(ABFETEM Leo 9112).To observe the liquid 
sample by SEM, special treatment was 
necessary to dry up the wet samples before SEM 
scan. As direct air-drying of the samples would 
cause damage due to surface tension of the 
evaporating water, critical point drying (CPD) 
was performed to prevent such damage before 
viewing under SEM (JSM 6400 SEM, Jeol) at 
different magnification [11, 12].  
 
Particle size distribution and zeta potential 
measurement 
 
Zeta potential (ZP) evaluates the stability of a 
colloidal system. It is a measurement of the 
repulsive forces between particles. Particles with 
larger repulsive forces are less likely to 
aggregate and would be more stable. Generally, 
particles with ZP < -30 mV or > +30 mV are 
normally stable [13]. Each sample solution was 
inserted into the cell and ZP was measured with 
a zetasizer (Zetasizer Nano Series, Malbern 
Instrument). This procedure was repeated three 
times and the result of the mean and standard 
deviation recorded.  
  
Construction of standard calibration curve  
 
DS solutions (in fresh phosphate buffer, pH=7.4) 
with a concentration range of 10 - 50 μg/mL were 
prepared. Absorbance was measured by UV 
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spectrophotometry (UV-1601 Shimadzu) at a 
wavelength of 300 nm and a standard calibration 
curve was constructed using Microsoft Excel 
2007 program.  
 
Evaluation of entrapment efficiency  
 
To study entrapment efficiency of the liposome, 
the mixture was centrifuged (Universal 32) for 1.5 
h at 9000 rpm, the supernatant was collected, 
and the absorbance measured by UV 
spectrophotometry at 300 nm [12]. The 
measurement was carried out in triplicate for 
each sample. Entrapment efficiency (EE) of the 
liposomes was determined as in Eq 1 
 
     EE(%) = {(Ci – Cf)/Ci} x 100 ……………. (1) 
 
where Ci is the initial concentration of drug used 
in formulating the liposomes and Cf is the 
concentration of drug in the supernatant          
 
In vitro drug release study 
 
To measure in vitro release of DS from the 
liposomes, 100 mg of liposome was added into a 
dialysis bag (MW, 12000). The bag was closed at 
both ends and placed in 50 ml of fresh PBS 
medium (pH 7.4) at 37 oC at 60 rpm under sink 
conditions [14,15].  
 
At predetermined time intervals, 2 mL of the 
medium was withdrawn and determined using 
UV spectrophotometer; the same volume of fresh 
fluid was used to replenish the release mediun. 
The release test was continued for 120 h. The 
absorbance of the release samples, diluted as 
necessary with release medium, was measured 
spectrophotometrically at 300 nm. The results 
recorded are the mean values of triplicate 
measurements for each liposome batch. 
Cumulative DS released at various time points 
were plotted using Microsoft Excel 2007 and 
computed as in Eq 2. 
 
Drug release (%) = (Ct/Co) x 100 ………. (2) 
 
where Ct is the concentration of drug released at 




Each value was expressed as the mean ± SD. 
One-way analysis of variance (ANOVA) was 
applied to analyze the data, followed by Scheffe 
post-hoc test using SPSS 15 [for Windows 7]. 




Morphology of liposomes  
 
TEM and SEM (Figure 1) images show that the 
liposomes were formed in all the formulations. FI 
and FII, which contained higher proportions of 
PC produced large and well-defined spherical 
vesicles; however, FIII, IV, V and VI which had 
palm oil fraction content of 20, 33.33, 46.67 and 
56.67, respectively, produced smaller, slightly 
deformed vesicles. These results shows however 
there is possibility of preparation liposomal drug 
delivery systems with other natural products such 
as palm oil fractions, but the role of PC in 
formation, shape and size of liposomes is not 
negligible, formulation with higher percentage of 
PC produces more spherical vesicles in bigger 
size. 
 
          
            (a)                                 (b)                                                                                          
 
Figure 1: (a) TEM images of designed liposome, 
magnification 16000x; (b) SEM images of designed 
liposome magnification 17000x.  
 
Particle size and zeta potential of liposomes 
 
As it can be seen in Table 2, the particle size of 
the liposomes decrease from FI to FVI and the 
ZP values confirm the system stability. Results 
demonstrated in figure 2 shows zeta potential 
has close relationship with the percentage of PC 
and palm oil fractions in the formulations. While 
replacing palm oil fractions with PC, zeta 
potential changed to -50.7 from -31.2 mV. 
Introduction of 46 and 56 % of palm oil fractions 
significantly modified zeta potential to -42.8 and -




Based on the calibration curve of DS in PBS, the 
regression equation obtained was A = 0.0213 x 
C + 0.056, where A is the absorbance at the 
wavelength of 300nm, and C is the concentration 
of Diclofenac sodium (DS); the regression 
coefficient was R2 = 0.9936. 
 
Entrapment efficiency (EE) 
 
Table 2 shows that formulation FVI, with an EE 
of 77.8 % of DS, had the highest entrapment  
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         Table 1: Composition of liposome formulations 
 
Formulation Content of lipids (%w/w) 
PC CH Palmitic 
acid 




FI 66.67 33.33 - - - - 
FII 56.67 33.33 1.60 1.20 0.60 6.60 
FIII 46.67 33.33 3.20 2.40 1.20 13.20 
FIV 33.33 33.33 5.33 4.00 2.00 22.00 
FV 20.00 33.33 7.47 5.60 2.80 30.80 
FVI 10.00 33.33 9.07 6.80 3.40 37.40 
 
Table 2: Mean particle size, zeta potential and entrapment efficiency of the liposomes 
 
  Formulation Mean particle size 
(nm, ±SD) 
Mean zeta potential 
(mV) 
Mean entrapment 
efficiency (%, ±SD) 
     FI 439 ±15 -31.2 ±3.3 70.78 ±0.41 
     FII 421 ±12 -29.4 ±2.0 60.14 ±7.48 
     FIII 387 ±13 -29.3 ±2.4 55.63 ±2.75 
     FIV 392 ±21 -34.3 ±1.4 30.98 ±8.28 
     FV 360 ±11 -42.8 ±1.4 42. 25 ±4.43 
     FVI 300 ±10 -50.7 ±4.9 77.84 ±5.85 
 
 
efficiency and formulation FIV with an EE of 31.0 
% had the least. 
 
In vitro drug release 
  
Figure 3 illustrates the in vitro release 
through106 hours for total release of DS from 
liposomes. DS release for FI was about 10 % 
through 12 h. It slightly increased until release 
was complete after 106 h. FII and FIII released 
drug of up to 44 and 46 %, after 12 h 
respectively, and DS release for both was 
complete after 72 h. FIV gradually released drug 
in 24 h but release increased more rapidly to 85 
% after 80 h. There was a slow release of FV 
during the first 6 h but it was followed by a sharp 
rise reaching the 91 % in 48 h. DS release from 




Figure 3: Cumulative release of diclofenac sodium in 
PBS (pH 7.4). Key: F1 (♦), FII (■), FIII (○), FIV (-), FV 




DS liposomes obtained in this study were 
medium-sized, with values ranging from 300 to 
439 nm depending on the proportion of PC in the 
system. This might be due to interactions 
between the lipid layers of liposome with DS. 
This is according to finding of Lopes which stated 
due to interaction of DS anion with the 
ammonium group of PC, the size of liposome 
that entraps DS reduced significantly, as the drug 
incorporated into the liposome [16]. Furthermore, 
large standard deviations found for mean particle 
size may be due to the broad heterogeneous 
sizes of the liposome. 
 
The ZP data indicate that there were repulsive 
forces between particles in colloidal systems and 
thus confirm the stability of the system.  A ZP < -
30 mV could result in particle aggregation and 
lead to caking and eventual spoilage. In this 
regard, FII and III with lower negative ZP would 
be less stable while FI, FIV, FV and FVI higher 
negative ZP would be more stable. A previous 
study suggests that interaction of DS with PC 
may adversely affect the structure and hence 
stability of the liposomes [13]. It was also 
observed that the liposomes were less stable the 
higher the proportion of PC, and more stable the 
higher the proportion of palm oil fractions. 
  
Entrapment efficiency decreased as the 
concentration of palm oil lipids increased. 
Hathout obtained a maximum entrapment 
efficiency of approximately 40 % and this is 
higher than the 30 % entrapment found in the 
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present study [17].  Imura has stated that drug 
entrapment increases as PC concentration rises, 
and hence the lower entrapment found in our 
study may be due to the smaller level of PC in 
the formulations [18].  
 
FII and FIII with lower negative ZP and would be 
less stable while FI, FIV, FV and FVI higher 
negative ZP would be more stable. A previous 
study suggests that interaction of DS with PC 
may adversely affect the structure and hence 
stability of the liposomes [16]. It was also 
observed that the liposomes were less stable the 
higher the proportion of PC, and more stable the 
higher the proportion of palm oil fractions. 
 
Entrapment efficiency decreased as the 
concentration of palm oil lipids increased. The 30 
% entrapment found in the present study is less 
than that earlier reported by Hathout et al [17]. 
Imura has stated that drug entrapment increases 
as PC concentration rises, and hence the lower 
entrapment found in our study may be due to the 
smaller level of PC in the formulations [18].  
 
FII and FIII exhibited faster release among all 
formulations and achieved maximum 90 % 
release within 62 h. On the other hand, FIV and 
FI showed slower release after 6 h. Interaction of 
DS with PC might have caused deformity of the 
liposome besides affecting the stability and 
release pattern due to leakage of the drug from 
the unstable liposomes [16]. As the amount of 
PC decreased, the interaction is reduced and the 
stability of liposome increases. This may be the 
reason why FIV with a lower PC level exhibited 
slower release than FI which contained a higher 
PC content. Although FV and FVI contained 
higher concentrations of palm oil fractions, their 
liposomes were smaller.  
 
The slower drug release obtained from FV and 
FVI, compared to FII and FIII, may be attributed 
to their higher stability and ZP [12,13] plus 
according to Yamauchi drug release rate will 
increase as liposomal size shrinks [19]. The 
slower drug release obtained from FV and FVI, 
compared to FII and FIII, may be attributed to 
their higher stability and ZP [12,13]; drug release 




The results of this study demonstrate the 
potential application of palm oil fractions in the 
preparation of liposomal DS. Since the amount of 
palm oil in formulation will significantly affect drug 
loading and drug release, this compound will 
provides the opportunity to prepare DS 
formulations with the desired bioavailability. By 
increasing the content of palm oil fraction from 10 
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